DT
HealthMore in Health→
Teclistamab-Based Induction Shows Promise in Transplant-Eligible Multiple Myeloma
Key Takeaways
- Phase 2 trial tests teclistamab-based induction in transplant-eligible newly diagnosed multiple myeloma.
- High overall response rates and MRD negativity observed.
- Safety profile manageable with expected toxicities.
- Potential new standard of care if confirmed in larger studies.
DE
DT Editorial Team··via nature.com